Newark, New Jersey – January 26, 2023 – BioCentriq, Inc.—a New Jersey-based, cell and gene therapy contract development and manufacturing organization (CDMO)—announced today that they’ve completed a study designed to test transfection of T-cells with GFP mRNA for evaluation of cell viability, transfection efficiency, and post transfection growth using Kytopen’s Flowfect® technology. [Read more…]
Athersys Provides MultiStem Clinical Update
Enrollment completed in second cohort of MATRICS-1 trial in hemorrhagic trauma
Enrollment reaches halfway mark in MASTERS-2 trial in ischemic stroke
CLEVELAND–Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, today provided an update on ongoing clinical trials with MultiStem for the treatment of patients following hemorrhagic trauma (MATRICS-1) and for the treatment of ischemic stroke (MASTERS-2). MultiStem is a proprietary off-the-shelf stem cell product in late-stage clinical trials for acute ischemic stroke, as well as trauma and other inflammatory conditions. [Read more…]
CooperSurgical® Announces More than 11,000 Families Have Enrolled in Newborn Possibilities Program®
Program provides free cord blood and tissue processing to qualifying families in need.
TRUMBULL, Conn., Jan. 5, 2023 — CooperSurgical, a global leader in fertility and women’s health, shared that more than 11,000 families have enrolled in the Newborn Possibilities Program® through their Cord Blood Registry® (CBR®) brand. Through the Newborn Possibilities Program, CBR offers free cord blood and tissue processing and five years of storage for families with a qualifying medical need. [Read more…]
How to find the right end-to-end developer for manufacturing your cGMP-compatible iPSCs
Introduction
From β-islets for diabetes (1) to dopaminergic neurons (Figure 1) for Parkinson’s disease (2), induced pluripotent stem cell (iPSC)-derived, haplotyped, and multiplex-engineered allogeneic cell therapeutics empower the development of effective and safe Cell and Gene Therapy Products (CGTs) that could be manufactured on a large scale in a cost-effective manner and provide a functional cure for diseases that plague humankind today. [Read more…]
BioCentriq Announces Successful Tech Transfer From Avenge Bio for Manufacturing of Drug Product AVB-001 Resulting in Dosing of First Patient in Phase 1/2 Clinical Trial
Newark, New Jersey, January 17, 2022 – BioCentriq, Inc.—a New Jersey-based, cell and gene therapy contract development and manufacturing organization (CDMO)—announced today that they have successfully completed tech transfer of AVB-001 from client Avenge Bio and initiated manufacturing of clinical grade material, which will support Avenge Bio’s ongoing phase 1/2 clinical trial.
- « Previous Page
- 1
- …
- 133
- 134
- 135
- 136
- 137
- …
- 338
- Next Page »